Can a drug combo shield lungs from radiation damage?

NCT ID NCT06634056

Recruiting now Disease control Sponsor: University Health Network, Toronto Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 07, 2026 · Updated 3 times

Summary

This study tests whether taking pentoxifylline and vitamin E during chemoradiation can prevent lung injury (pneumonitis) in stage III non-small cell lung cancer patients. 150 participants will receive either the drug combo or a placebo for 6 months. The goal is to see if this reduces side effects and improves quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pentoxifylline and vitamin E (α-tocopherol)
What this could lead to: If it works, this could reduce the risk of radiation-induced lung injury and improve quality of life for lung cancer patients.
What could go wrong: This is a Phase 2 trial with 150 participants, so results are still early. The drugs may not prevent lung injury, and side effects from the combination are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma radiation pneumonitis prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER RADIATION INDUCED LUNG INJURY (RILI)

Contacts and locations

Locations

University Health Network - Princess Margaret Cancer Centre
RECRUITING

Toronto, Ontario, M5G 2C1, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.